195 related articles for article (PubMed ID: 9816039)
1. Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: the issue of sequence.
Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Neuwelt EA
Clin Cancer Res; 1995 Jul; 1(7):731-9. PubMed ID: 9816039
[TBL] [Abstract][Full Text] [Related]
2. The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.
Dahlborg SA; Petrillo A; Crossen JR; Roman-Goldstein S; Doolittle ND; Fuller KH; Neuwelt EA
Cancer J Sci Am; 1998; 4(2):110-24. PubMed ID: 9532413
[TBL] [Abstract][Full Text] [Related]
3. Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery.
Remsen LG; McCormick CI; Sexton G; Pearse HD; Garcia R; Mass M; Roman-Goldstein S; Neuwelt EA
Neurosurgery; 1997 May; 40(5):1034-40; discussion 1040-2. PubMed ID: 9149262
[TBL] [Abstract][Full Text] [Related]
4. Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system.
Jahnke K; Kraemer DF; Knight KR; Fortin D; Bell S; Doolittle ND; Muldoon LL; Neuwelt EA
Cancer; 2008 Feb; 112(3):581-8. PubMed ID: 18072268
[TBL] [Abstract][Full Text] [Related]
5. Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas.
Hall WA; Doolittle ND; Daman M; Bruns PK; Muldoon L; Fortin D; Neuwelt EA
J Neurooncol; 2006 May; 77(3):279-84. PubMed ID: 16314949
[TBL] [Abstract][Full Text] [Related]
6. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in the treatment of cerebral metastasis.
Fortin D; Gendron C; Boudrias M; Garant MP
Cancer; 2007 Feb; 109(4):751-60. PubMed ID: 17211866
[TBL] [Abstract][Full Text] [Related]
7. Unexpected neurotoxicity of etoposide phosphate administered in combination with other chemotherapeutic agents after blood-brain barrier modification to enhance delivery, using propofol for general anesthesia, in a rat model.
Fortin D; McCormick CI; Remsen LG; Nixon R; Neuwelt EA
Neurosurgery; 2000 Jul; 47(1):199-207. PubMed ID: 10917363
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of tumor cell exposure to [14C]methotrexate after intracarotid administration without and with hyperosmotic opening of the blood-brain and blood-tumor barriers in rat brain tumors: a quantitative autoradiographic study.
Shapiro WR; Voorhies RM; Hiesiger EM; Sher PB; Basler GA; Lipschutz LE
Cancer Res; 1988 Feb; 48(3):694-701. PubMed ID: 3335031
[TBL] [Abstract][Full Text] [Related]
10. Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models.
Ewend MG; Williams JA; Tabassi K; Tyler BM; Babel KM; Anderson RC; Pinn ML; Brat DJ; Brem H
Cancer Res; 1996 Nov; 56(22):5217-23. PubMed ID: 8912860
[TBL] [Abstract][Full Text] [Related]
11. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
[TBL] [Abstract][Full Text] [Related]
12. Cognitive outcomes and long-term follow-up results after enhanced chemotherapy delivery for primary central nervous system lymphoma.
McAllister LD; Doolittle ND; Guastadisegni PE; Kraemer DF; Lacy CA; Crossen JR; Neuwelt EA
Neurosurgery; 2000 Jan; 46(1):51-60; discussion 60-1. PubMed ID: 10626935
[TBL] [Abstract][Full Text] [Related]
13. A randomized clinical trial comparing concurrent and alternating thoracic irradiation for patients with limited small cell lung carcinoma. "Petites Cellules" Group.
Lebeau B; Urban T; Bréchot JM; Paillotin D; Vincent J; Leclerc P; Meekel P; L'Her P; Lebas FX; Chastang C
Cancer; 1999 Oct; 86(8):1480-7. PubMed ID: 10526276
[TBL] [Abstract][Full Text] [Related]
14. Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience.
Fortin D; Desjardins A; Benko A; Niyonsega T; Boudrias M
Cancer; 2005 Jun; 103(12):2606-15. PubMed ID: 15880378
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model.
Neuwelt EA; Pagel MA; Hasler BP; Deloughery TG; Muldoon LL
Cancer Res; 2001 Nov; 61(21):7868-74. PubMed ID: 11691805
[TBL] [Abstract][Full Text] [Related]
16. Late magnetic resonance imaging features of leukoencephalopathy in children with central nervous system tumours following high-dose methotrexate and neuraxis radiation therapy.
Kellie SJ; Chaku J; Lockwood LR; O'Regan P; Waters KD; Wong CK;
Eur J Cancer; 2005 Jul; 41(11):1588-96. PubMed ID: 16026694
[TBL] [Abstract][Full Text] [Related]
17. Rodent model of chemoradiotherapy-induced white matter necrosis.
Taylor EM; Geyer JR; Milstein JM; Shaw CM; Geraci JP; Wootton P; Hubbard BA; Bleyer WA
NCI Monogr; 1988; (6):59-64. PubMed ID: 3352790
[TBL] [Abstract][Full Text] [Related]
18. [Reversible opening of the blood-brain barrier in the chemotherapy of malignant gliomas].
Heimberger K; Samec P; Podreka I; Binder H; Suess E; Reisner T; Deecke L; Steger G; Hiesmayr M; Dittrich C
Wien Klin Wochenschr; 1987 May; 99(11):385-8. PubMed ID: 3113082
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
[TBL] [Abstract][Full Text] [Related]
20. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
